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Setting appropriate cutoff values and the use of a highly sensitive analytical method allow for correct classification of the smoking
status. Urine-saliva pairs samples of pregnant women in the second and third trimester, and saliva only in the first trimester were
collected. Offline SPE and LC-ESI-MS/MS method was developed in the broad concentration range (saliva 0.4–1000ng/mL, urine
0.8–4000ng/mL). The mean recoveries were 3.7±7.6% for urine and 99.1±2.6% for saliva. LOD for saliva was 0.12ng/mL and for
urine 0.05ng/mL; LOQ was 0.4ng/mL and 0.8ng/mL, respectively. Intraday and interday precision equaled, respectively, 1.2% and
3.4%forurine,and2.3%and6.4%forsaliva.Therewasastrongcorrelationbetweensalivarycotinineandtheuncorrectedcotinine
concentrationinurineinthesecondandthirdtrimestersofpregnancy.Thecutoffvalueswereestablishedforsaliva12.9ng/mLand
urine 42.3ng/mL or 53.1𝜇g/g creatinine with the ROC curve analysis. The developed analytical method was successfully applied to
quantify cotinine, and a significant correlation between the urinary and salivary cotinine levels was found. The presented cut-off
valuesforsalivaryandurinarycotinineensureacategorizationofthesmokingstatusamongpregnantwomenthatismoreaccurate
than self-reporting.
1. Introduction
The most commonly used biomarker of exposure to tobacco
smoke is cotinine, as a metabolite of nicotine. The measure-
mentofthecotinineconcentrationinvariousbiologicalfluids
is directly proportional to the degree of exposure to nicotine
[1]. The determination of cotinine is recommended for the
assessment of active tobacco smoking, monitoring of envi-
ronmentaltobaccosmoke(ETS)exposure,andimpactevalu-
ationofsmokingcessationprograms[2].Themostimportant
advantage of using cotinine as a biomarker of tobacco smoke
a n dE T Si st h ef a c tt h a ta b o u t7 2 %o fn i c o t i n ei sc o n v e r t e d
to cotinine [3] and the half-life of cotinine averages about
17 hours, in comparison to the one averaging 2-3h in case
of nicotine [4]. The total nicotine content in tobacco (by
weight of tobacco) averaged 10.2mg [5], while the nicotine
intake per cigarette averaged 1.04mg [6], representing about
10%.
According to the Global Adult Tobacco Survey (GATS)
in Poland, in 2009, approximately 24% of women aged 15–49
years were smokers (out of whom 21% were daily cigarette
smokers) [7] .B a s e do nt h eP r e g n a n c y - r e l a t e dA s s e s s m e n t
Monitoring Survey (PrAMS), the most recent results show
thatevenmorethan12%ofpregnantwomeninPolandsmoke
[8].
The effect of tobacco smoking is not limited to the one of
nicotine, which is responsible for addiction to smoking,
b u ta l s oi n v o l v e st h ei n fl u e n c eo fv a r i o u st o x i cs u b s t a n c e s
released from burning cigarettes, like carbon monoxide,
PAHs, heterocyclic compounds, N-nitrosoamines, aromatic2 BioMed Research International
amines, N-heterocyclic amines, aldehydes, or volatile hydro-
carbons, among which 69 are known carcinogens [9–11]. The
most important adverse health effects associated with mater-
nal cigarette smoking are premature rupture of membranes,
placental abruption or preeclampsia [12], uteroplacental
insufficiency, and reducing the blood flow to the fetus.
Maternalsmokingmayalsoresultinlowerbirthweightofthe
newborns [11] .Ba sedo nth ea n al y s i spe rf o rm edi nP o la n d ,i n
thenewbornsprenatallyexposedtoETS,thebirthweightwas
lower by 335g±90.3 than that in the case of the nonexposed
newborns (𝑃 < 0.001)a ft e ra d j u s t m e n tf o rm a t e r n a le d u -
cational level, marital status, prepregnancy weight, child
gender, and gestational age [13]. Maternal nicotine exposure
may cause changes in the development and maturing of the
offspring’s lungs, which can result in the organ being more
susceptible to disease and likely to manifest reduced lung
function [14]. Smoking during pregnancy may have long-
term consequences on the neurobehavioral development of
children [8].
Due to numerous highly adverse effects of smoking dur-
ing pregnancy, there is a need to monitor the extent of expo-
sure, spread the knowledge of these effects to the fetus, and
promotesmokingcessation.Evaluationofthesmokingstatus
among pregnant women is based mainly on a self-reported
questionnaire. However, only a confirmation by a laboratory
a n a l y s i sm a yl e a dt oc o r r e c ta n dr e l i a b l ec l a s s i fi c a t i o ns i n c e
pregnant women (and not only they) are reluctant to admit
that they smoke.
Interindividual variability in the metabolism of nicotine
is due to the gender and ethnic differences in the activity of
enzymes (CYP2A6 and UGT1A) and, to some extent, genetic
polymorphisms of the CYP2A6 gene [15]. Like many other
physiological processes, also the metabolism of nicotine
changes during pregnancy. The observed variability in the
metabolic clearance of cotinine may markedly increase by
140% during pregnancy, resulting in a half-life shorter by
nearly 50% than the one in the nonpregnant state [16].
The explanation of these changes could be the influence
of a higher concentration of estradiol during pregnancy [17],
which induces the activity of CYP2A6 responsible for the
metabolism of nicotine [18].
As reported by Rebagliato et al. [19], the salivary cotinine
level was significantly lower during pregnancy, compared
withthepostpartumone.Therefore,itisnecessarytoidentify
a cutoff value to avoid misclassification of smoking and non-
smoking pregnant women.
The ROC analysis is increasingly used to determine the
cut-off values for biomarkers of exposure to tobacco smoke
[20–23].
Theprimaryaimofthisstudywastoestablishtheoptimal
cut-off value for cotinine in saliva and urine of pregnant
womeninPolandandtocomparethediagnosticeffectiveness
of three smoking tests: cotinine in saliva and in urine and in
urine with creatinine correction. The secondary one was to
develop a sensitive and specific method for determining the
cotinine level in urine and saliva in a broad range of con-
centrations. Finally, our aim was also to estimate the utility
of these matrices for both rapid screening used in order to
identify potential smokers and more accurate determination
of the degree of exposure to tobacco smoke, especially that
concerning pregnant women.
2. Methods
2.1. Population. From the biobank of the Polish Mother
and Child Cohort Study (REPRO PL), saliva-urine samples
collected in trimester II and III of 69 women were selected as
w e l la st h es u rv e yd a t ao nt h es m o k i n gs t a t u so ft h ep r e g n a n t
woman,thesmokinghabitofherhusband/partner,andacon-
sent to smoking in the apartment. In addition, each of these
w o m e nh a das a l i v as a m p l et a k e nd u r i n gt h efi r s tt r i m e s t e r
of pregnancy. The complete description of the cohort was
publishedelsewhere[24]. In short, the inclusion criteria were
single pregnancy up to 12 weeks of gestation, no assisted
conception, no pregnancy complications, and no chronic
diseases as specified in the study protocol [24]. The mean age
of 69 women was 26.41 ± 4.97 y e a r s .B a s e do nt h es u r v e y
data, it was found that in the first trimester 19/69 women
were smokers and, in the second and third trimesters, this
ratio equaled 17/69. Smoking was permitted in 52% of the
apartmentsinthefirsttrimesterofpregnancy,butinthethird
trimester such permission to smoke at home decreased by
approximately 9%.
To find the correlations between the matrices, we ana-
lyzed saliva and urine samples collected at the same time.
2.2. Standards and Reagents. Cotinine (98%), internal stand-
ard-cotinine-d3 (98%), and ammonium acetate (98%) were
obtained from Sigma Aldrich. Acetonitrile and Methanol
Ultra Gradient HPLC Grade were supplied by Baker. Acetic
acid (>99%) was purchased from Fluka. Ultrapure water was
obtained from Milli-Q-Plus, Ultra-PureWater System (Milli-
pore USA). All working standards of cotinine and cotinine-
d3 were prepared in acetonitrile and stored at −20
∘C. Solid
phase extraction manifold was maintained on Supelco, and
OASIS HLB LP 96-Well Plate 60𝜇m( 6 0m g )w a ss u p p l i e db y
Waters(USA).ControlurinelyophilizedClinCheck/Control,
for toxic organic compounds, was purchased from Recipe
Chemicals (Germany).
2.3. Biological Samples Collection. Saliva was collected from
p r e g n a n tw o m e ni n t oaS a l i v e t t ew i t hc i t r i ca c i d( S a r s t e d t ,
German y).Theamo un to fa p p r o xima tely1 -2mLo fsalivawas
easily obtained by having the women chew a cotton swab, at
least30minaftereatingordrinking.Aclear,fluidsamplewas
obtained by centrifuging the Salivette and used for analysis.
A 50mL volume of morning urine was collected from
pregnantwomentoa100mLpolypropylenecontainer(Bene,
Poland). All saliva and urine samples were transported to the
laboratory in a cool box and stored at −20
∘Cu n t i la n a l y s i s .
2.4. Samples Preparation. Urine and saliva samples were
thawed before the analysis, thoroughly mixed, and trans-
ferred into 2.0mL polypropylene tubes. The samples were
centrifugedfor10minat11000rcf(MIKRO120,HettichZen-
trifugen,Tuttlingen,Germany).To0.25mLofurineor0.5mL
of saliva, water and 20𝜇L of internal standard (cotinine-d3)
were added and mixed vigorously. Each well of the OasisBioMed Research International 3
Table 1: Validation parameters of the LC-MS/MS method of determination of cotinine in saliva and urine.
LOD
[ng/mL]
LOQ
[ng/mL]
Range of linearity
[ng/mL]
Correlation coefficient
𝑟
2
Uncertainty
(𝑘=2 )[ % ]
Accuracy
[%] Recovery
∗ [%]
Urine 0.05 0.8 0.8–4000 0.9997 9.3 4.27 93.72 ± 7.6
Saliva 0.05 0.4 0.4–1000 0.9993 6.0 2.33 99.10 ± 2.6
∗All values are means ± SD.
HLBextractionplatewasprewashedwith2mLofacetonitrile
followed by 2mL of water. Then, the samples were placed
o nt h ep l a t ea n dw a s h e dw i t h1 . 0 m Lo fw a t e r( i nc a s eo f
saliva samples) and 1.0mL of 20% methanol in water (in
case of urine samples). The analytes were eluted with 1mL
of acetonitrile, and 20𝜇L of the extract was injected into the
chromatographic system.
2.5. Calibration. The working solutions were prepared by
appropriate dilutions of the standard stock solutions. The
standard stock solutions of 1mg cotinine or cotinine-d3/mL
were further diluted with acetonitrile to obtain the working
solutions of cotinine (10𝜇g/mL, 400ng/mL, and 20ng/mL)
and cotinine-d3 (2.5𝜇g/mL). Calibration standards were
prepared for saliva at the following concentrations: 0.2; 0.5;
1.0; 5.0; 10; 50; 100; 200; 500ng/mL and for urine 0.2; 0.5; 1.0;
5.0; 10; 50; 100; 200; 500; 1000ng/mL. All working solutions
were stored at −20
∘C. Calibration curves were generated
using linear regression with 1/X weighting.
2.6. Liquid Chromatography-Mass Spectrometry. The chro-
matographic separation was performed using the Waters
2695 Alliance LC System (Waters, USA) on the analytical
column X-Terra MS C 18 3.5𝜇m2 . 1× 150mm (Waters).
The following mobile phase was used: A 7% (water
containing 0.04% of ammonium acetate with 0.05% of acetic
acid) and B 93% (acetonitrile) with an isocratic mode and
flow rate of 0.2mL/min.
The Micromass Quattro Micro API tandem mass spec-
trometer (Waters, USA) was coupled to the HPLC Alliance
system. The mass spectrometer was operated in the electro-
spray positive mode; the capillary was kept at 1.0kV and the
source temperature was maintained at 130
∘C, the desolvation
gas flow was 600L/h and the desolvation temperature was
kept at 350
∘C, and the cone energy was 33V and the collision
energy was 21eV for both cotinine and cotinine-d3.Th e
specific ion transitions for cotinine and cotinine-d3 were
monitored in a multiple reaction monitoring mode (MRM)
with a dwell time of 0.3s.
2.7. Creatinine Correction. The creatinine level was deter-
mined according to the Jaffe automated method. Urine
sampleswithacreatinineconcentrationlowerthan0.3g/Lor
higher than 3.0g/L were excluded [25].
2.8. Statistical Analysis. Receiver operating characteristic
(ROC) curve analysis was used for three purposes: to test
the performance of the diagnostic system (how close to 1 is
A U C ) ,t oc o m p a r et h ep e r f o r m a n c eo ft h et h r e et e s t s ,a n dt o
establish the optimal cut-off values for cotinine in saliva and
in urine and creatinine-corrected concentration in urine.
Statisticalanalysiswasperformedbasedonthemeasurement
of cotinine in the biological material, taking into account
the self-reported information on smoking and the data from
the questionnaires concerning the ETS exposure at home of
samplesdonors.Thelevelofstatisticalsignificancewaskeptat
𝑃 < 0.05.TheROCanalysismoduleoftheIBMprogramSPSS
ver. 20.0 (IBM SPSS) was used for the ROC curves analysis
and comparison of the area under the curve (AUC).
The correlation between the cotinine concentrations in
saliva and urine was analyzed with the IBM SPSS Statistics
20.0.
3. Results
3.1. Optimization of the HPLC-MS/MS Conditions. The mass
spectrometer conditions were optimized by monitoring coti-
nineandcotinine-d3 ionpairsforquantificationintheMRM
mode. The best results were achieved with m/z transitions of
quantification traces, 177.2 > 80.2; 180.2 > 80.2,a n dc o n -
firmation, 177.2 > 98.2; 180.2 > 101.2,f o rc o t i n i n ea n d
cotinine-d3,r e s p e c t i v e l y .
The retention time of cotinine and cotinine-d3 was
a p p r o x - i m a t e l y2 . 5 m i n ,a n dt h et o t a lr u nt i m ee q u a l e d
6min. The use of the structurally identical internal standard
(cotinine-d3) eliminated most of the quantification errors.
3.2. Linearity. The relationship between the response and
concentration of cotinine in a range of 0.4–1000ng/mL (for
saliva samples) and 0.8–4000ng/mL (for urine samples) was
linear, with the correlation coefficient (𝑟) of the calibration
curve𝑟 > 0.998orhigher.Detailedparametersofthemethod
validation are presented in Table 1.
3.3. Sensitivity. The limit of detection (LOD) defined as the
concentration of an analyte that gives at least a 3:1, signal to-
noise ratio was 0.12ng/mL (for saliva) and 0.05ng/mL (for
urine), and the limit of quantification (LOQ), defined as the
concentration of an analyte that gives at least a 10:1 signal-
to-noise ratio, was 0.4ng/mL (for saliva) and 0.8ng/mL (for
urine).
3.4. Precision and Recovery. The intraday and interday preci-
sions of the method were estimated by the analysis of control
urine (ClinCheck, Level 1) and saliva samples (saliva from
smokers) at the concentration of 248ng/mL of urine (control
range 198–298ng/mL) and about 250ng/mL of saliva on the
same day and on four consecutive days (Table 2).
To determine the recovery of the extraction from the
urine and saliva samples, seven different cotinine levels were4 BioMed Research International
Table 2: Recovery of cotinine in urine and saliva samples.
Expected value
[ng/mL]
Measured
∗
[ng/mL] Recovery [%]
Urine
Before spiking
0.884 ± 0.055ng/mL
0.8 0.63 ± 0.01 78.5
40 38.8 ± 3.4 97
80 76.4 ± 3 95.6
120 113.1 ± 4.6 94.3
2000 1977 ± 96.3 98.8
3800 3728 ± 76.6 98.1
Saliva
Before spiking
0.701 ± 0.041ng/mL
0.4 0.40 ± 0.037 100.5
20 20.06 ± 0.56 100.3
40 38.4 ± 4.2 95.9
80 80 ± 2.9 100.5
120 113.6 ± 2.2 94.7
500 506.1 ± 7.36 101.1
900 907 ± 10.5 100.7
∗All values are means ± SD.
Table 3: Intraday and interday precision of cotinine in urine and
saliva samples.
Sample Intraday precision Interday precision
𝑛 Mean
[ng/mL]
RSD [%] 𝑛 Mean
[ng/mL]
RSD [%]
Urine 32 5 7 . 5 1.2 12 259.0 3.4
Saliva 42 4 3 . 3 2.3 16 244.9 6.4
added. Three repetitions of each concentration level were
analyzed,andtheratioofthemeasuredamountstotheadded
amounts was calculated (Table 3).
3.5. Tests of Usability: Smoking and Nonsmoking Women. To
test the usability of the method, in total 138 pairs of urine-
s a l i v as a m p l e sw e r ea n a l y z e d( 6 9p a i r si nt r i m e s t e rI Ia n d6 9
pairsintrimesterIII),aswellas69salivasamplescollectedin
trimesterI.Inallurineandsalivasamples,theconcentrations
of cotinine were above LOD (Table 4).
Toassessthecorrelationsbetweenthematrices,thelinear
regression and Pearson’s correlations were calculated. The
results are shown in Figure 1. The correlations between the
saliva and the uncorrected cotinine concentrationin urine in
trimester II (𝑟 = 0.932) and III (𝑟 = 0.925)w e r eh i g h e rt h a n
the aggregated data of trimester II and III (𝑟 = 0.851), both
being statistically significant (𝑃 < 0.01). Similar trends were
observed for the correlation between saliva and creatinine-
corrected cotinine in urine, but the corresponding 𝑟 values
were lower, that is, 0.720, 0.865, and 0.780, for trimester II,
III, and the total period of pregnancy, respectively.
To verify the smoking status, various questionnaires are
usuallytakenintoaccount.Inthisstudy,wetookintoaccount
information on the smoking status obtained in the survey.
The research model was used to compare different matri-
ces (saliva, urine) and the creatinine correction of cotinine
concentrations of urine. Also, an analysis was conducted of
t h ee ff e c to ft h ep e r i o di nt h ep r e g n a n c yo nt h ec u t - o ffv a l u e .
Statistical analysis was performed to compare the cotinine
concentrations in the samples taken from women at different
periods of pregnancy. Saliva samples were collected during
periodic medical examinations in trimester I, II, and III of
pregnancy and urine samples in trimester II and III.
Receiver operating characteristic (ROC) curve analysis is
a graphical and quantitative technique used for determina-
tionoftheoptimalcut-offvalue.Selectingtheoptimalcut-off
value for individual biomarkers of smoking was conducted
usingtheYouden’sindex,J,whichisdefinedasthemaximum
sumofsensitivityandspecificitydecreasedby1,thatis:𝐽max =
(sensitivity + specificity)−1[26]. The cut-off value is “opti-
mal” when the index has the maximum value.
On the basis of the content of cotinine in saliva, the
cut-off values for the corresponding uncorrected cotinine in
urine and creatinine-corrected urine were calculated. The
optimized cut-off values and parameters of ROC curves
analysis of cotinine in saliva and urine for pregnant women
are shown in Table 5.
When choosing the optimal cut-off value, it is important
to take into account both sensitivity and specificity, and the
maximum value of Youden’s index was the decisive factor.
ROC analysisshowed that theoptimalcut-offvaluesepa-
rating smokers and nonsmokers for saliva varies depending
o nt h ep e r i o do fp r e g n a n c ya n de q u a l s3 1 . 9 n g / m Lf o rt h e
firsttrimester,18.1ng/mLforthesecondone,and11.47ng/mL
for the last one with the sensitivity of 100% and specificity of
96% for all tests. In addition, the optimum cut-off value was
determined on the level of 18.8ng/mL (98.3%, 89.6, 𝑛 = 241)
for cotinine in saliva throughout pregnancy (trimesters I, II,
and III).
Theoptimalcut-offvalueforcotinineintheurinesamples
collected in trimester II was higher than in trimester III both
for the urine-53ng/mL versus 34.44ng/mL and the crea-
tinine corrected concentration-68.35𝜇g/g creatinine versus
48.53𝜇g/g creatinine (Table 5).
TheROCanalysisforthecombinedsamplestakenduring
t h ep e r i o df r o mt h es e c o n dt ot h et h i r dt r i m e s t e ro fp r e g -
nancy showed lower cut-off values for the cotininelevel in all
tested matrices, 12.45ng/mL for saliva and 42.3ng/mL and
53.09𝜇g/g creatinine for urine with the sensitivity equaling
100% and specificity of 95%. (Table 5).
The determined cut-off for cotinine in saliva samples
collected at the beginning of the pregnancy was 31.9ng/mL
(sensitivity 100%/specificity 96%).
These values were established to distinguish between
pregnant smokers and nonsmokers.
4. Discussion
We developed and validated the method for rapid, sensitive,
and specific determination of cotinine in urine and saliva.
By achieving the low limit of quantification (0.4ng/mL for
saliva and 0.8ng/mL for urine), the presented method can be
useful to assess the exposure to tobacco smoke as ETS and
active smoking. Using the noninvasive methods of sampling
biological material, like urine or saliva, the smoking status
can be more easily assessed, especially with lower volume of
biological fluids, than in other studies.BioMed Research International 5
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Figure1:Comparisonoftheurinaryandsalivarycotinineconcentrations,dependingonthetrimesterofpregnancyandcreatininecorrected
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Table 4: Cotinine in saliva and urine classification based on self-reporting smoking status.
𝑁 AM SD GM 95% CI
Nonsmoking
Saliva
Trimester I 50 5.99 6.88 4.437 4.376–4.498
Trimester II 52 4.86 8.42 3.190 3.116–3.263
Trimester III 52 3.86 4.14 3.060 3.024–3.096
Urine Trimester II 52 10.78 29.31 4.497 4.242–4.751
Trimester III 52 10.27 32.50 3.070 2.787–3.352
Urine corrected Trimester II 52 14.33 35.61 5.531 5.221–5.841
Trimester III 52 14.43 30.14 5.546 5.267–5.826
Smoking
Saliva
Trimester I 19 175.77 91.69 151.88 150.561–153.199
Trimester II 17 174.42 98.67 141.92 140.424–143.425
Trimester III 17 181.40 139.97 128.45 126.319–130.577
Urine Trimester II 17 1021.97 632.79 747.67 738.044–757.292
Trimester III 17 500.15 368.45 341.72 336.115–347.323
Urine corrected Trimester II 17 1758.4 1703.8 1017.31 991.395–1043.22
Trimester III 17 1133.2 1685.8 545.10 519.465–570.741
Table 5: Optimized cutoff values of cotinine in saliva and urine for pregnant women (Youden’s index 0.956 ± 0.0084).
Smoking AUC
∗ SE 95% CI Cutoff Sensitivity Specificity
Yes No
Saliva [ng/mL]
Trimester I 19 50 0.998 0.003 0.992–1.000 31.90 100% 96%
Trimester II 17 52 0.997 0.004 0.989–1.000 18.10 100% 96%
Trimester III 17 52 0.997 0.004 0.989–1.000 11.47 100% 96%
Trimesters II & III 34 104 0.997 0.003 0.992–1.000 12.85 100% 96%
Urine [ng/mL]
Trimester II 17 52 0.997 0.004 0.989–1.000 53.00 100% 96%
Trimester III 17 52 0.991 0.008 0.976–1.000 34.44 100% 94%
Trimesters II & III 34 104 0.994 0.004 0.997–1.000 42.31 100% 95%
Urine corrected [𝜇g/g]
Trimester II 17 52 0.995 0.005 0.986–1.000 68.35 100% 96%
Trimester III 17 52 0.990 0.008 0.974–1.000 48.53 100% 94%
Trimesters II & III 34 104 0.993 0.004 0.984–1.000 53.09 100% 95%
∗𝑃 < 0.0001.
A number of other analytical methods have been applied
for the measurement of cotinine in urine or saliva includ-
ing immunological methods, for example, enzyme linked
immunosorbent assay (ELISA, LOD = 1.3ng/mL). However,
cross-reactivity is still the major concern for immunological
methods, especially with nicotine metabolites: 3
򸀠-hydroxyc-
otinine and 3
򸀠-hydroxycotinine-glucuronide [27]. The most
commonly used analytical techniques are gas chromatog-
raphy with flame-ionization detection (GC-FID, LOQ =
500ng/mL) [28], mass spectrometry (GC-MS, LOQ =
10ng/mL) [29], and liquid chromatography with mass spec-
trometry (UPLC-MS/MS, LOQ = 1.1ng/mL) [30, 31]. These
m e t h o d sh a v eb e e nu s e dt od i s t i n g u i s hs m o k e r sf r o mn o n -
smokers. Many gas chromatographic methods are character-
ized by relatively high limits of quantification, which makes
it more complicated to access the ETS exposure. In this case,
the method of choice should make it possible to achieve a
limit of detection lower than 1ng/mL [32]. In order to evalu-
ate such low concentrations, it is very important to minimize
ionsuppression,inparticularinthechromatograph ymethod
coupled with mass spectrometryor tandem mass spectrome-
try.Manyanalyticalmethodsdonotuseinternalstandardsor
usestructurallydifferentinternalstandardsthanradiolabeled
compounds,suchasmilrinone[33],diphenylamine[34],and
acetaminophen [35], which may contribute to the increase of
ion suppression [36].
A current state-of-the-art method for determination of
cotinine in biological material is liquid chromatography with
mass spectrometry (LC-MS/MS) and atmospheric pressure
or electrospray ionization which gives high sensitivity. The
results of our study offered a method characterized by
improved sensitivity, selectivity, and high throughput inBioMed Research International 7
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Figure 2: ROC curves analysis of smoking status based on questionnaires and measurement of cotinine in saliva and in urine and creatinine
corrected cotinine in urine are shown in Figure 2.
comparison to other conventional techniques. The struc-
turally identical deuterated internal standard (cotinine-d3)
increasestheselectivityofthemethod,eliminatestheeffectof
ion suppression, and results in higher precision and accuracy
of the measurement. The advantage of the use of the 96-well
extractionplateisthepossibilitytocleanupmultiplesamples,
blank, and quality control samples, in parallel under the
same conditions. This sample preparation procedure makes
it possible to achieve a lower limit of detection (LOD =
0.05ng/mL) by minimizing the matrix effect with only 0.25
mL of urine or 0.5 mL of saliva needed for the analysis.
So far, many studies have been published concerning
cotinine cutoff points, yet only a few included pregnant
women. In 1998, Klebanoff et al. [37]e s t a b l i s h e das e r u m8 BioMed Research International
cotinine cut-off value 10ng/mL for pregnant women which
correspondstotheconcentrationinsalivaof12.5ng/mL.This
estimationisbasedonthestudyofJarviswhodiscoveredthat
the concentration of cotinine in saliva is 1.25 times higher
than in serum [38]. For the nonpregnant women-14ng/mL
serum[39]a n d12n g/ mL[40].In Japan,foralarge validation
study (𝑛 = 5128) on tobacco smoke exposure during
pregnancy, the cutoff for serum cotinine was established at
11.48ng/mL which corresponds to 14.35ng/mL in saliva [41].
As for saliva, the values obtained for pregnant women were
on the level of 13ng/mL [42]a n d2 4n g / m L[ 43, 44].
Interindividualvariabilitiesinthemetabolismofnicotine
areduetothegender-andethnicity-dependentdifferencesin
the activity of enzymes (CYP2A6 and UGT1A) or, to some
extent, genetic polymorphisms of the CYP2A6 gene [15].
Asforurine,theresultsrecordedamongpregnantwomen
were 100ng/mL [45] and among the nonpregnant ones-
50ng/mL [39], 200ng/mL [46], and 550ng/mL [21].
From the physiological point of view, pregnancy is a
dynamic process, duringwhich thereincreases,inter alia, the
volumeofblood(30–40%)[47],distributionvolumeandrate
of nicotine metabolism [16].
Probably, these are the main reasons for which the cut-
offvaluesforcotinineinsalivaandurineatdifferentstagesof
pregnancymaydiffermateriallyfromthosesetforthegeneral
population. In our study, we compared changes in the con-
centration of cotinine in the samples taken from women at
different times of pregnancy during periodic medical exami-
nations.Thecut-offvaluesdeterminedfortrimesterII,andIII
forbothsalivaandurineindicate aslightchange (reduction).
However, the difference between the values determined for
the first trimester for saliva, that is, 31.9ng/mL, was signifi-
cantly higher for those determined for the second trimester
and third trimester, respectively, 18.1ng/mL and 11.47ng/mL.
In view of the relatively small changes in the metabolism of
nicotineinearlypregnancy,thecut-offvalueof31.9ng/mLfor
that period may be taken as a defining value for nonpregnant
women.
The correct determination of the smoking status is par-
ticularly important in epidemiological studies assessing the
effects of exposure to environmental factors on the outcome
of pregnancy, where smoking is an important confounding
factor that should be taken into account in the analysis and
interpretation of results.
M i n i m i z i n gt h en u m b e ro fm i s c l a s s i fi e dc a s e s ,w ee s t i -
mated the optimal cutoff point for pregnant women as
12.85ng/mL for salivary cotinine and 42.3ng/mL or 53.1𝜇g/g
creatinine for urinary cotinine. The observed slight decrease
ofcotininecut-offvaluesbothforsalivaandurineintrimester
III as compared with II confirms the previous findings.
These findings correspond to those obtained in a Nakayima
and Yokoi’s study where a large interindividual variability in
cotinine N-glucuronidation (ca. 89-fold) in human micro-
somes in vitro was reported [14]. The hypothesis concerning
a decrease of the free cotinine concentration in the body
fluidsofpregnantwomenmayclarifyourobservationbutstill
needs verification in the further research.
In our study, cotinine concentrations in urine samples
were compared with those in saliva samples to estimate the
differences and correlations between the matrices. For the
urinary and salivary cotinine levels in the second and third
trimesters, high correlations were observed, better for saliva-
urine than for saliva-creatinine-corrected urine. That con-
firms the findings of a previous study on the lesser use of
creatinine correction [48, 49]. The mean urinary creatinine
concentration in our study was 0.89g/L (with the results
<0.3g/L,themeanwas0.82g/L),whichisamuchlowerresult
comparedwiththenonpregnantwomenaged20–49,withthe
mean being 1.2g/L [50]. A more reliable parameter for the
assessment of diuresis would be obtained if the collection of
24-hour urine samples was used. However, in epidemiologic
studies, spot samples are more practical than 24hr urine
samples [50].
Forthemonitoringofexposuretotobaccosmoke,usually
only one type of biological samples is collected. The choice of
the sample type depends on the purpose of the study and the
analytical technique that is available in the laboratory. This
is particularly important in case of nonsmokers, where the
expected concentrations are very low. Our study shows that
the levels of cotinine in urine are about 4–5.5 times higher
than in saliva, depending on the use of creatinine correction.
On the other hand, saliva is a matrix that is easier to clean
up than urine. All the advantages and disadvantages of those
m a t r i c e sm u s tb et a k e ni n t oa c c o u n tw h i l es e l e c t i n gt h e
method of sample preparation and analytical technique. In
this study, we used saliva samples for rapid screening of the
smoking status. Urinary cotinine can be used to estimate
more precisely the level of exposure to tobacco smoke, espe-
cially in nonsmokers, and to differentiate the nonexposed
nonsmokers and exposed nonsmokers. In our analysis, we
took into account only the survey data as a criterion for
classification as smokers-nonsmokers, but a widespread lack
of acceptance for smoking during pregnancy may be a cause
of untrue answers.
In 2007, Zieli´ nska-Danch et al. set a cut-off value for coti-
nine in urine of 500ng/mL for the general population [21].
In later studies, Zieli´ nska-Danch et al. [22] using ROC curve
analysis obtained the value of 327 micrograms/g creatinine.
Exposure to the second-hand smoke is region specific,
and in some countries a low level of exposure results in a
much lower cutoff cotinine value. Until 2009, many studies
referred to the cut-off value established by Jarvis et al. [39]
that equaled 14ng/mL serum for the general population,
w h i l et h en e wv a l u eo f4 . 4 7 n g / m L( c o r r e s p o n d i n gt o
5.59ng/mL saliva) for women was established as a result of
the NHANES survey [20]. However, the authors proposed
a general cut-off point of 3ng/mL or ethnic-specific values
between 1 and 6ng/mL serum [20]. Benowitz et al. [20]
established also a urine cut-off value of 15ng/mL using
an extrapolation of the above results and average ratios of
cotinine in urine and plasma.
The cut-off value for cotinine in urine (determined by
Goniewicz et al. [23]) equaling 31.5ng/mL (𝑛 = 637)r e p r e -
sents the multiethnic population, including the Poles, that is
likely to be exposed to tobacco smoke in the same way as the
group of pregnant women studied in our research.
The optimal saliva cut-off value of 12.9ng/mL is com-
parable to that equaling 14.35ng/mL saliva (derived formBioMed Research International 9
11.48ng/mL plasma) obtained for Japanese pregnant women
[41].Mostlikely,thehighcutoffpointconcerningPolishpreg-
nant women represents a similar second-hand exposure to
tobacco smoke. Taking into account the smoke-free law, the
substantialreductionoftheETSexposurecanbeexpected,as
well as a decrease of tobacco smoke biomarkers (cotinine in
salivaandurine).Asaconsequence,alsoloweracut-offvalue
might be established.
5. Conclusion
The results of the analytical method validation indicate that
the developed procedure can be applied for routine deter-
mination of cotinine in urine and saliva samples. Achieving
a low limit of quantification (0.4ng/mL for saliva and
0.8ng/mL for urine) allows not only distinguishing between
smokers and nonsmokers but also quantifing the exposure to
environmental tobacco smoke and degree of active smoking.
Our results showed a significant correlation between the
urinary and salivary cotinine levels. Our study presents for
thefirsttimeresultsofROCcurveanalysisusedtodetermine
the cut-off values for the assay of cotinine in saliva and urine
and in creatinine-corrected urine as a marker of exposure
to tobacco smoke in women during different periods of
pregnancy in order to distinguish their status of smoking.
This is the first such study of pregnant women in Poland.
The ROC analysis with the application of the Youden’s
index helped to determine the optimal cut-off value for
cotinine in saliva (18.9ng/mL) and in urine (42.3ng/mL and
53.1𝜇g/g creatinine) for the first time for pregnant women in
Poland.
The analysis of the diagnostic usefulness of cotinine
determination in saliva and urine and the evaluation of the
usefulness of the creatinine correction of the cotinine level
showed that all three proposed cut-off values are character-
ized by high sensitivity and specificity.
Our results suggest that, during the interpretation of
the analysis of cotinine, the period of pregnancy when the
samples of urine or saliva are taken for the assessment of
exposure to tobacco smoke may have some significance.
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